Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
KLAC$130.53-19.12(-12.78%)KLA Declares Regular Cash Dividend4:30:14 PM ETMU$665.03-130.43(-16.40%)Micron Announces Board of Directors Retirement4:30:06 PM ETMU$665.03-130.43(-16.40%)Micron Announces Board of Directors Retirement4:30:00 PM ETKO$95.78-0.10(-0.10%)DRIVX Moves Toward Final Presale Stage, Unveils Fleet Expansion and Transparent Vesting Strategy4:19:08 PM ETCRWD$218.60-22.38(-9.29%)Why CrowdStrike and cybersecurity stocks got crunched in Thursday's rout4:12:00 PM ETNVDA$182.50-17.79(-8.88%)Nvidia's Huang is asked to brief Congress on reported Chinese spy relationship4:09:56 PM ETLRCX$191.05-30.23(-13.66%)Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly Dividend4:05:00 PM ETSKHY$124.32-18.76(-13.11%)Why SK Hynix Plunged Today4:01:39 PM ETNVDA$182.50-17.79(-8.88%)Is Nvidia Still a Millionaire-Maker Stock?3:51:00 PM ETTSLA$341.91-43.27(-11.23%)SpaceX and Tesla Stock Plunges Have Wiped About $450 Billion in Value Since the Midterms. Is It Time to Buy?3:43:35 PM ETGOOGL$280.14-8.89(-3.08%)Google plans $17 billion Wyoming data center amid rising threats of curbs3:43:13 PM ETNOW$101.21-7.70(-7.07%)Arista Networks vs. ServiceNow: Which Technology Stock Is a Better Buy for 2027?3:43:02 PM ETGOOGL$280.14-8.89(-3.08%)BREAKINGVIEWS-Global muscle will sift puny data center providers3:30:09 PM ETAMD$408.18-80.51(-16.47%)Is AMD Stock a Buy as AI Revenue Soars?3:19:00 PM ETGEV$770.56-61.95(-7.44%)GE Vernova vs. NextEra Energy: Which Industrials Stock Is a Better Buy for 2027?3:17:11 PM ETBRK-A$857,487.54-9,063.79(-1.05%)Berkshire Hathaway Reports Nov. 7 With Its Stock at a Record. Its Cash Pile Is the Number to Watch.3:17:02 PM ETC$118.48+0.68(+0.58%)UPDATE 10-Brent crude jumps, settles up over $3 after tanker attacks3:15:37 PM ETCLX$99.10-0.10(-0.10%)Global Surface Disinfectant Market to Hit US$ 7.5 Bn by 2031, Registering at 7.4% CAGR: Wissen Research3:14:00 PM ETTM$218.30+18.94(+9.50%)ERI’s John Shegerian Describes the Current State of Rare Earth Mineral Recovery at World Remanufacturing Summit in Tokyo3:09:00 PM ETMRVL$135.35-24.56(-15.36%)Marvell Just Dropped 49% in a Month: Is MRVL Stock Hopeless or Ready for a Rebound?3:03:21 PM ETSPCX$123.50-12.33(-9.08%)Bull v. Bear: SPCX Faces Uncertainty as Midterm Results Pressure TSLA Merger3:00:38 PM ETINTC$52.09-6.19(-10.62%)Intel Shares Rise 6% To Intraday High After Key Trading Signal3:00:27 PM ETAMD$408.18-80.51(-16.47%)Advanced Micro Devices vs. Taiwan Semiconductor Manufacturing: The AI Sell-Off Is Exposing a Critical Difference Investors Shouldn't Ignore for 20273:00:02 PM ETHSY$177.43+2.93(+1.68%)Hershey vs. Coca-Cola: Which Consumer Goods Stock Is a Better Buy for 2027?2:51:29 PM ET

CVRX · NASDAQ

CVRx, Inc.

$1.47 -0.10 (-6.37%)

Company overview

CVRx, Inc., a commercial-stage medical device company, develops, manufactures, and commercializes neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction, also known as systolic heart failure. It sells its products through a direct sales force, as well as sales agents and independent distributors in the United States, Germany, the rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ
Market cap
$39.2M
Employees
206
Headquarters
Minneapolis, MN
Website
cvrx.com
CEO
Kevin Hykes
Listed
June 30, 2021
P/E
-0.73
Dividend yield
0.00%

Company financials

Revenue
$59.1M
Gross profit
$50.5M
Operating income
-$50M
EBITDA
-$48.8M
Net income
-$52.7M
EPS
-$2.02
Total assets
$99.7M
Total debt
$59M
Gross margin
85.53%
Net margin
-89.15%
Earnings yield
-137.42%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

0.982.844.706.568.42
CVRX 1D NASDAQ O1.40H1.60L1.40C1.58+0.20 (+14.49%)Vol368.17K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CVRXCVRx, Inc. Stock news BRIEF-CVRx Q3 Revenue USD 13.832 Million Vs. IBES Estimate USD 13.9 Million Reuters
CVRXCVRx, Inc. Press release CVRx Reports Third Quarter 2026 Financial and Operating Results GlobeNewswire
CVRXCVRx, Inc. Press release CVRx to Participate in Upcoming Investor Conferences GlobeNewswire
CVRXCVRx, Inc. Press release CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026 GlobeNewswire
CVRXCVRx, Inc. Legal Oct 01, 2026, 14:24 ET HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop Hagens Berman, a national… PR Newswire
CVRXCVRx, Inc. Press release CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026 GlobeNewswire
CVRXCVRx, Inc. Legal HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages GlobeNewswire
CVRXCVRx, Inc. Press release CVRx Appoints John Landry as Chief Financial Officer GlobeNewswire
CVRXCVRx, Inc. Legal HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop PR Newswire
CVRXCVRx, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX GlobeNewswire
CVRXCVRx, Inc. Stock news CVRx Secures Devoted Health Coverage for Barostim Therapy Zacks Investment Research
CVRXCVRx, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims PRNewsWire
CVRXCVRx, Inc. Legal HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop PRNewsWire
CVRXCVRx, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX GlobeNewswire
CVRXCVRx, Inc. Press release CVRx Responds to Letter from Pointillist Family Office GlobeNewswire
CVRXCVRx, Inc. Legal CVRx, Inc. Investors Who Suffered Losses Should Contact Block & Leviton LLP Newsfile Corp
CVRXCVRx, Inc. Press release Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer PRNewsWire
CVRXCVRx, Inc. Press release CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy GlobeNewswire
CVRXCVRx, Inc. Legal HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop PRNewsWire
CVRXCVRx, Inc. Legal CVRx, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm Newsfile Corp
See more
FAQ

Questions about CVRx, Inc.

What does CVRx, Inc. do?
CVRx, Inc., a commercial-stage medical device company, develops, manufactures, and commercializes neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction, also known as systolic heart failure. It sells its products through a direct sales force, as well as sales agents and independent distributors in the United States, Germany, the rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
What is CVRX's market cap?
CVRx, Inc. (CVRX) is a listed stock with a live quote. The latest market cap on this page is $39.2M.
Where is CVRx, Inc. headquartered?
CVRx, Inc. is headquartered in Minneapolis, MN.
How do I get CVRX news from the API?
Call GET /v1/news?tickers=CVRX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CVRX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CVRX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CVRX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs